Amanta Healthcare Limited – Investor Presentation Summary

Key Operational Highlights

  • Total production capacity of 39.79 crore units across Large Volume Parenterals (LVP) and Small Volume Parenterals (SVP).
  • LVP (excluding SteriPort) capacity: 5.7 crore units; SVP capacity: 20.91 crore units; SteriPort (LVP) capacity: 6.62 crore units.
  • Current capacity utilization stands at 96%, indicating strong demand visibility.
  • The company has a portfolio of 47 products registered in 120 countries.
  • Key drivers of operational performance include high capacity utilization, a diverse product portfolio across 6 therapeutic segments, and a robust distribution network of 320+ distributors.

Segment-wise Performance

  • Revenue share across categories: Not explicitly broken down by percentage for Q1, but overall business includes IV Fluids, Diluents & Injectables, Ophthalmic, and Respiratory solutions.
  • The SteriPort product line (LVP) contributed 44% of total revenue in FY26.
  • The SVP segment contributed 20% of revenue in FY26 and operates at EBITDA margins of 22–27%.

Financial Highlights

Revenue: ₹69 crore (Q1FY27)

EBITDA: ₹15 crore (Q1FY27)

PAT: ₹3 crore (Q1FY27)

YoY/QoQ comparison: Q1FY27 revenue of ₹69 crore represents a 5% growth over Q1FY26 revenue of ₹66 crore. EBITDA was flat YoY at ₹15 crore.

Drivers of financial performance: Sustained revenue trajectory despite inflationary cost increases and overheads.

Key Risks: Not explicitly disclosed in the presentation.

Geographical Revenue Split

Domestic vs Export/Regional Revenue: Not specified for Q1FY27. The company exports to 21 countries across emerging and semi-regulated markets, with a focus on portfolio expansion in the UK, Latin America, South East Asia, and Africa.

Balance Sheet Snapshot

Net Debt/Equity: 1.06x (FY26), reduced from 3.50x in FY23.

Reserves: Part of 'Other Equity' which stood at ₹181 crore (FY26).

Current Assets: ₹238 crore (FY26); Current Liabilities: ₹141 crore (FY26).

Working Capital/Leverage Metrics: Net Working Capital days were 141 days in FY26.

Financial Health Insights: Significant deleveraging with over 70% reduction in debt-to-equity since FY23. Cash and cash equivalents stood at ₹81 crore as of FY26.

Capex & Cash Flow Health

Capital Expenditure: A solar power project with a total cost of ₹34.8 crore is under implementation, largely debt-funded.

Free Cash Flow: Not specified.

Operating Cash Flow: Cash flow from operating activities was ₹48 crore in FY26.

Net Debt Movement: Not specified for the quarter.

Investment Rationale: Capex is focused on capacity scale-up, transition to renewable energy, and accelerated product pipeline/new product rollouts.

Strategic & R&D Initiatives

Investments in Innovation: The company has in-house product development and a dedicated regulatory affairs team. It is the first in India to use Injection Stretch-Blow Moulding (ISBM) technology for IV fluids.

Expected impact on growth: The SteriPort capacity expansion is expected to generate incremental revenue of ₹110-120 crore per year and expand EBITDA margins by 3-4%.

Strategic Rationale: Expanding high-margin SVP portfolio (Inhalation Solutions, OTC, Preservative Free unit doses) and increasing focus on exports to drive higher margins.

Industry Trends & Business Environment

Macro/Industry Trends: Not explicitly discussed in the presentation.

Impact on Company: Not specified.

Management Commentary & Growth Outlook

Strategic Outlook: Operations from expansion (likely SteriPort) are expected to commence from Q2FY27. Captive solar generation started from the end of Q1FY27. Further focus on new product development to enrich the product portfolio.

FY Guidance: The company aims for a revenue CAGR of 20%+ and an EBITDA margin of 25%+ over the next two years.

Market Share Targets: The company holds a 50–60% domestic market share in the PP IV bottle segment.

Risks and Opportunities: Not explicitly highlighted.

ESG Updates

  • A ₹34.8 crore solar power project is under implementation to transition to renewable energy, expected to generate annual savings of ₹9 crore.
  • The facility holds ISO 14001:2015 (Environmental Management) and ISO 45001:2018 (Occupational Health & Safety) certifications.